Basic Duphaston Information

• INN (International Nonproprietary Name): Dydrogesterone.
• Brand Names Available In Canada (English): Duphaston is the primary international brand name for dydrogesterone.
• ATC Code: G03DB01.
• Forms & Dosages: Tablet, 10 mg strength, usually supplied in blisters of 20 tablets.
• Manufacturers In Canada (English): Laboratoires Abbott Products (Abbott/AbbVie) is the primary global marketing authorisation holder.
• Registration Status In Canada (English): Not specified in the supplied registry data for Canada; product is registered in most European countries, Russia and multiple Asian markets, and is prescription-only in markets where it is approved.
• OTC / Rx Classification: Prescription-only (Rx) in registered markets according to the available product monographs.

Latest Research Highlights

Patients ask: Does the newest research support duphaston for luteal support and miscarriage prevention?

International systematic reviews and meta-analyses up to 2023 generally report that dydrogesterone is effective for luteal-phase support and for preventing recurrent miscarriage, with a tolerability profile favourable versus some synthetic progestins.

Canadian observational cohorts and fertility clinic audits from 2020–2024 report pregnancy continuation rates for dydrogesterone that are comparable to micronized progesterone in routine practice settings.

Direct randomised head-to-head trials in Canada are limited, so clinicians typically interpret international trial data alongside local observational evidence.

European pharmacovigilance summaries since 2018 show low rates of serious adverse events, with safety signals mainly involving mood changes and rare hepatic events.

Canadian fertility programmes commonly weigh cost, bilingual counselling and product availability when choosing progestogens for patients.

Clinicians and patients should check Health Canada and provincial formularies for the latest listings and regulatory notes before prescribing or importing products.

Clinical Effectiveness In Canada

One common worry is whether duphaston works as well here as in Europe or Asia.

Randomised trials from outside Canada support dydrogesterone for luteal-phase support and certain bleeding disorders.

Canadian real-world evidence is mainly observational, coming from fertility clinics and hospital obstetrics departments rather than large Canadian RCTs.

Dydrogesterone is the INN and is most commonly packaged as 10 mg oral tablets when supplied internationally.

At the time of writing, Duphaston has a smaller presence in Canada than in Europe or Asia, and many Canadian clinics use micronized progesterone (Prometrium) or medroxyprogesterone alternatives that are widely covered on provincial formularies.

Comparative outcomes reported in clinic audits include similar pregnancy rates and miscarriage reduction when dydrogesterone is used, with adverse-event profiles comparable to micronized progesterone in observational series.

• Pregnancy Rates: Observational reports show comparable continuation rates versus micronized progesterone.
• Miscarriage Reduction: Meta-analyses internationally support benefit for recurrent miscarriage protocols; Canadian RCT data are limited.
• Adverse Events: Mostly mild (breast tenderness, headache, nausea); watch for mood or hepatic signals.

Indications And Expanded Uses

People often ask which conditions duphaston treats versus when doctors use it off-label.

Standard indications include secondary amenorrhea, luteal insufficiency, dysfunctional uterine bleeding, threatened and habitual abortion, endometriosis, dysmenorrhea and as an adjunct in hormone replacement therapy with estrogen.

Canadian clinicians generally follow these international indications and sometimes use dydrogesterone off-label for selected recurrent miscarriage protocols based on meta-analytic evidence.

1. Approved Indication: Treatment for progesterone-responsive conditions such as secondary amenorrhea and luteal insufficiency in markets where it is registered.
2. Off-Label Use: Some recurrent miscarriage protocols and individual fertility clinic regimens, used after specialist discussion and informed consent.

• Typical Regimens: See dosage table below for per-indication dosing.
• Evidence Strength: Stronger for luteal support and recurrent miscarriage in meta-analyses; weaker for endometriosis and PMS where comparative trials are fewer.

Clinicians should reference Health Canada and provincial college guidance before prescribing off-label and ensure culturally safe, bilingual counselling that discusses alternatives such as micronized progesterone or medroxyprogesterone.

Composition And Brand Landscape

Patients ask whether duphaston is the same everywhere and who makes it.

INN is dydrogesterone and the primary marketed brand internationally is Duphaston, usually supplied as 10 mg tablets in blisters of 20.

Laboratoires Abbott Products (Abbott/AbbVie) is the main marketing authorisation holder, with licensed local partners in some regions.

In Canada, brand presence is limited compared with Europe and Asia and there is no dominant Canadian-branded dydrogesterone with broad market penetration reported in the supplied registries.

Available forms are oral tablets only, ATC code is G03DB01, and the molecule is classed as a plain progestogen without androgenic, estrogenic or glucocorticoid activity.

Pharmacies in Canada should confirm stock with chains such as Shoppers Drug Mart, Rexall, Jean Coutu and London Drugs and be prepared for special-order timelines and bilingual labelling considerations.

Contraindications And Special Precautions

Patients often want to know who should avoid duphaston.

Absolute contraindications include allergy to dydrogesterone, known or suspected progestogen-dependent tumours, active or severe liver disease, and undiagnosed vaginal bleeding.

Relative contraindications that require monitoring include a history of depression, thromboembolic disorders, uncontrolled hypertension, renal impairment and diabetes mellitus.

• Absolute Contraindications: Allergy to dydrogesterone; progestogen-dependent tumours; severe liver disease; undiagnosed vaginal bleeding.
• Relative Contraindications: History of depression; thromboembolic risk; uncontrolled hypertension; renal impairment; diabetes.

Monitoring checklist for prescribers and pharmacists should include baseline liver tests when clinically indicated, blood pressure checks, and mood screening in patients with psychiatric history.

Special attention is required for elderly patients, Indigenous populations and people in remote communities where follow-up testing may be delayed.

Provide bilingual counselling and clear red-flag guidance such as jaundice, sudden severe mood change or calf pain indicating possible thrombosis.

Dosage Guidelines

One common question is, "How much duphaston should I take and for how long?"

Dydrogesterone tablets are 10 mg each and common regimens follow international practice with specialist adjustments in Canadian reproductive clinics.

• Secondary Amenorrhea: 10 mg twice daily, often days 11–25 of cycle.
• Luteal Support (Infertility): 10 mg daily, typically days 14–25 or continuous for cycles used in ART.
• Dysfunctional Uterine Bleeding: 10 mg twice daily for 5–7 days as indicated.
• Threatened Abortion: Initial 40 mg loading then 10 mg every 8 hours, continued as directed.
• Habitual Abortion: 10 mg daily continued at least through week 20 per specialist protocol.
• Endometriosis: 10–20 mg daily, cycle days 5–25 or continuous, per clinician decision.

Typical treatment durations vary by indication: luteal support commonly 3–6 cycles, amenorrhea or endometriosis often 3–6 months, and habitual abortion support continued to at least 20 weeks gestation.

Patients with severe hepatic impairment should avoid use and dose adjustments are not well established for elderly patients.

Typical Regimen Summary: 10 mg tablets; common luteal support dose 10 mg daily; amenorrhea often 10 mg twice daily on cycle days 11–25.

Interactions Overview

People worry about mixing duphaston with other medications like anticoagulants or antidepressants.

Dydrogesterone is metabolised by the liver and, although it has fewer clinically significant interactions than some synthetic progestins, caution is recommended with strong CYP3A4 inducers or inhibitors.

Anticonvulsants and rifampin-like antibiotics may reduce progestogen levels and warrant monitoring.

Co-prescription with anticoagulants such as warfarin requires pharmacist review and INR monitoring if clinically indicated.

• Major Interaction Classes: CYP3A4 inducers (e.g., certain antiepileptics), CYP3A4 inhibitors, antibiotics with rifampin-like effects, anticoagulants, and some antidepressants.
• Monitoring Recommendations: Check INR for warfarin co-therapy, watch for altered efficacy with strong enzyme modulators, and order liver tests when clinically warranted.

There are no specific food restrictions, but advise patients to avoid excessive alcohol to reduce hepatic strain.

Cultural Perceptions And Patient Habits

Many patients ask whether duphaston will be accepted by their family or community.

Online Canadian forums and fertility support groups report concerns about access, bilingual information, and mood-related side effects when choosing a progestogen.

Patients often prefer non-androgenic progestogens and ask about differences between dydrogesterone and micronized progesterone or medroxyprogesterone acetate.

Urban patients in centres such as Toronto, Vancouver and Montreal generally get faster access to specialty pharmacies and fertility clinics.

Rural and Northern residents may rely on telemedicine, special-order pharmacies or cross-border sourcing and face longer delivery timelines.

Indigenous and newcomer communities require culturally safe counselling, translation, and transparent discussion of cost and historical health-system concerns.

• Patient Concerns: Access, bilingual leaflets, mood effects, brand trust.
• Counselling Elements: Bilingual materials, pharmacist follow-up, clear safety guidance and options for alternatives like Prometrium.

Availability And Pricing Patterns

People often ask where to buy duphaston and how much it will cost in Canada.

Duphaston is widely available in Europe and Asia but was discontinued in the USA and UK, and availability in Canada is limited according to the supplied registries.

Clinics and pharmacies in Canada may special-order dydrogesterone or use alternative progestogens that are more consistently stocked.

In our online pharmacy, duphaston is available without a prescription, with discreet delivery to Canada (English) in 5-14 days.

Provincial drug plans like Ontario Drug Benefit, BC PharmaCare and RAMQ are more likely to cover alternatives unless a DIN and formulary listing support reimbursement for dydrogesterone.

Ask a pharmacist for bilingual price quotes, patient-assistance programs, and possible compassionate supply from manufacturers when access is limited.

Comparable Medicines And Preferences

Patients want to know which options are similar to duphaston and why a clinician might choose one over another.

Main alternatives include norethisterone, medroxyprogesterone and micronized progesterone (Prometrium).

Dydrogesterone is attractive because it lacks notable androgenic, estrogenic or glucocorticoid activity, but it is oral-only and has limited Canadian branding compared with some alternatives.

• Choose Based On: Indication, patient preference for oral vs vaginal route, comorbidity profile, and provincial coverage.
• Patient Checklist: Efficacy, side effects, cost, bilingual counselling, and rural access options.

Frequently Asked Questions

Patients commonly ask clear, practical questions about duphaston.

Q: Is Duphaston approved in Canada?

A: Check Health Canada and DIN listings for the latest status; Duphaston is widely registered in Europe and Asia but has limited presence in North America according to supplied data.

Q: Can I import Duphaston from the US?

A: Duphaston was discontinued in the USA, and personal importation carries legal and regulatory risks; consult Health Canada guidance and a pharmacist before attempting cross-border procurement.

Q: What are common side effects?

A: Common reactions include breast tenderness, headache, nausea and spotting; severe mood changes or signs of liver dysfunction require urgent medical assessment.

Q: Will provincial drug plans cover Duphaston?

A: Coverage depends on DIN listing and formulary criteria for each program such as Ontario Drug Benefit, BC PharmaCare and RAMQ; prior-authority may be necessary.

For quick patient handouts, include the INN (dydrogesterone), the usual 10 mg tablet strength and practical advice about missed doses and storage below 30°C.

Guidelines For Proper Use

Pharmacists and patients both ask what safety checks to do before dispensing.

Best-practice recommends verifying indication, allergies, pregnancy status, liver disease history and concurrent anticoagulant use before dispensing.

• Pre-Dispense Checklist: Confirm prescription (or follow special-order procedure), check for contraindications, review current medications for interactions, and ensure patient receives bilingual counselling.
• Counselling Points: How to take tablets, missed dose advice (take as soon as remembered unless near next dose), storage under 30°C, and when to seek urgent care.

Pharmacists should document off-label uses in the patient record, provide bilingual labels and coordinate special-order procurement when necessary.

For rural patients, advise mail-order timelines, temperature-stable packaging and telepharmacy follow-up to ensure adherence and safety monitoring.

Delivery Across Canada (English)